CS
ALXN

Credit Suisse’s Alexion Pharmaceuticals ALXN Stock Holding History

Credit Suisse’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,900
Closed -$716K – 4676
2021
Q2 		$716K Hold
3,900
– – ﹤0.01% 3613
2021
Q1 		$596K Sell
3,900
-45,600
-92% -$7.05M ﹤0.01% 3661
2020
Q4 		$7.73M Buy
49,500
+19,200
+63% +$2.47M ﹤0.01% 1751
2020
Q3 		$3.47M Sell
30,300
-28,400
-48% -$3.06M ﹤0.01% 2032
2020
Q2 		$6.59M Buy
58,700
+52,400
+832% +$5.56M ﹤0.01% 1535
2020
Q1 		$566K Sell
6,300
-4,700
-43% -$461K ﹤0.01% 3039
2019
Q4 		$1.19M Sell
11,000
-13,500
-55% -$1.44M ﹤0.01% 2997
2019
Q3 		$2.4M Buy
24,500
+15,600
+175% +$1.76M ﹤0.01% 2331
2019
Q2 		$1.17M Buy
8,900
+3,700
+71% +$477K ﹤0.01% 2835
2019
Q1 		$703K Buy
+5,200
New +$647K ﹤0.01% 3148
2018
Q3 		– Sell
-45,700
Closed -$5.67M – 4082
2018
Q2 		$5.67M Hold
45,700
– – 0.01% 1645
2018
Q1 		$5.09M Buy
45,700
+10,700
+31% +$1.28M ﹤0.01% 1701
2017
Q4 		$4.19M Buy
35,000
+10,000
+40% +$1.22M ﹤0.01% 1899
2017
Q3 		$3.51M Sell
25,000
-25,000
-50% -$3.4M ﹤0.01% 2063
2017
Q2 		$6.08M Buy
+50,000
New +$5.82M 0.01% 1508

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Credit Suisse's ALXN Position: Q3 2021 in Review

Credit Suisse sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,744,843 shares — an estimated $321M sold.

Credit Suisse first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $321M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Credit Suisse reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Credit Suisse sold 1,744,843 Alexion Pharmaceuticals shares in Q3 2021, an estimated $321M.
  • Credit Suisse first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Credit Suisse's Alexion Pharmaceuticals position peaked at $321M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.